This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    NCT02828878
Previous Study | Return to List | Next Study

Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation

This study is currently recruiting participants.
See Contacts and Locations
Verified August 2017 by Cellect Biotechnology
Sponsor:
Information provided by (Responsible Party):
Cellect Biotechnology
ClinicalTrials.gov Identifier:
NCT02828878
First received: July 4, 2016
Last updated: August 8, 2017
Last verified: August 2017
  Purpose
Interventional, open label, Phase I/II, Safety and Proof-of-Concept Study, with a follow up period of 180 days after the transplantation of ApoGraft.

Condition Intervention Phase
Hematological Malignancies Biological: Allogeneic MPBC transplantation from matched related donor Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase I/II, Pilot, Staggered Four-Cohort Safety and Proof-of-Concept Study of ApoGraft in the Prevention of Acute Graft Versus Host Disease (aGvHD)

Resource links provided by NLM:


Further study details as provided by Cellect Biotechnology:

Primary Outcome Measures:
  • Overall incidence, frequency and severity of adverse events (AEs) potentially related to the product during the study [ Time Frame: 180 days from transplantation ]

Secondary Outcome Measures:
  • Determination of the optimal dose of FasL concentration that facilitates the biological activity of the ApoGraft process [ Time Frame: 180 days from transplantation ]
  • Time of neutrophils engraftment determined by number of days for reaching first of 3 consecutive days with ANC ≥ 500/mm3 [ Time Frame: 28 days from transplantation ]
  • Rate of neutrophils engraftment determined by number of days for reaching first of 3 consecutive days with ANC ≥ 500/mm3 [ Time Frame: 28 days from transplantation ]
  • Time of platelets engraftment determined by number of days for reaching first of 3 consecutive days with platelets ≥ 20,000/mm3 in the absence of platelet administration during the prior 7 days [ Time Frame: 180 days from transplantation ]
  • Rate of platelets engraftment determined by number of days for reaching first of 3 consecutive days with platelets ≥ 20,000/mm3 in the absence of platelet administration during the prior 7 days [ Time Frame: 180 days from transplantation ]
  • Incidence to development of aGvHD [ Time Frame: 180 days from transplantation ]
  • Time to development of aGvHD [ Time Frame: 180 days from transplantation ]
  • Non-relapse mortality [ Time Frame: 180 days from transplantation ]
  • Proportion of patients with disease relapse [ Time Frame: 180 days from transplantation ]
  • Proportion of patients with progression free and overall survival [ Time Frame: 180 days from transplantation ]

Estimated Enrollment: 12
Study Start Date: January 2017
Estimated Study Completion Date: September 2018
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ApoGraft
ApoGraft is a mobilized peripheral blood cell (MPBC) product derived from peripheral blood. There will be 4 cohorts, each differ in the amount of apoptotic mediator Fas Ligand (APO010) to which the graft is exposed during incubation prior to ApoGraft transplant, ranging from 10 ng/ml APO010 in Cohort 1, 25 ng/ml APO010 in Cohort 2, 50 ng/ml APO010 in Cohort 3, and 100 ng/ml APO010 in Cohort 4
Biological: Allogeneic MPBC transplantation from matched related donor

Detailed Description:

ApoGraft product is a mobilized peripheral blood cell product of a matched Related donor, collected via apheresis, which is exposed to the apoptotic mediator Fas Ligand (CD95L) prior to transplantation (Ex Vivo).

The study is designed to address the aspects of engraftment and Prevention of Acute Graft versus Host Disease (aGvHD) rate and/or severity in 12 Patients

STUDY DESIGN:

This is a phase 1/2, open-label, proof-of-concept, staggered 4-cohort clinical study. Each cohort will include 3 patients with hemato-oncology disorders eligible for allogeneic HLA-matched HSCT. Patients in all cohorts will undergo similar study procedures and evaluation. The cohorts will differ from each other in the amount of apoptotic mediator Fas Ligand (APO010) to which the graft is exposed during incubation prior to ApoGraft transplantation and HSCT, ranging from 10 ng/ml APO010 in Cohort 1, 25 ng/ml APO010 in Cohort 2, 50 ng/ml APO010 in Cohort 3 and 100 ng/ml APO010 in Cohort 4. APO010 is washed-out as part of the ApoGraft process and only trace amounts of APO010 are present in the final ApoGraft product

The study consists of a screening phase (subject and donor clinical assessment and screening tests), transplantation of ApoGraft, and a follow-up period of 180 days during and after hospitalization.

The study will progress from one cohort to the next based on an independent data safety monitoring board (DSMB) review and analysis of safety data

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Recipient/patient main inclusion criteria:

  1. Adult male or female subjects, 18-70 years of age.
  2. Subjects are eligible for allogeneic HLA-matched related HSCT for any hematological malignancies for which transplantation is appropriate with corresponding related donor. One of the following hemato-oncology disorders diagnosis is required:

    • Acute myelogenous leukemia (AML) and Acute lymphoblastic leukemia (ALL) in 1st or subsequent complete remission (CR)
    • Non-Hodgkin's disease (NHD) in CR by CT or PET/CT
    • Hodgkin's disease (HD) in 1st or subsequent CR by CT or PET/CT
    • Intermediate, High or Very High Risk Myelodysplastic syndrome (MDS) (IPSS-R criteria)
  3. The donor and recipient must have full match at the HLA A, B, C, DR and DQ loci.
  4. ECOG performance status score 0-1 at time of the screening visit.
  5. Subjects must have adequate organ function as defined in the study protocol
  6. Signed written informed consent to participate in the study.
  7. If female of childbearing potential, agree to use an acceptable method of birth control or be surgically sterile, and have a negative pregnancy test.

Donor main inclusion criteria:

  1. Adult male or female subjects, 18-65 years of age.
  2. Donor criteria according to standard WMDA criteria for donor selection. 3 Must have full match at the HLA A, B, C, DR and DQ loci with the recipient.

4. Signed written informed consent

Recipient/patient main exclusion criteria:

  1. Use of non-myeloabletive conditioning.
  2. Uncontrolled infections including sepsis, pneumonia with hypoxemia, persistent bacteremia, or meningitis within two weeks of the screening visit.
  3. Current known acute or chronic infection with HBV or HCV.
  4. Known human immunodeficiency virus (HIV) infection or AIDS.
  5. Subjects with severe or symptomatic restrictive or obstructive lung disease or respiratory failure requiring ventilator support.
  6. Subjects with other concurrent severe and/or uncontrolled medical condition, which could compromise participation in the study (i.e. active infection, uncontrolled diabetes, uncontrolled hypertension, congestive cardiac failure, unstable angina, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months and chronic liver or renal disease.
  7. Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder or any chronic condition susceptible, in the opinion of the investigator, of interfering with the conduct of the study.
  8. Organ allograft or previous history of allogeneic stem cell transplantation.
  9. Pregnancy or lactation.

Donor main exclusion criteria:

  1. HIV, HBV or HCV positive subjects.
  2. Pregnant or lactating women.
  3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02828878

Contacts
Contact: Yael Kenan, Ph.D 972-9-9741444 yael@cellectbio.co

Locations
Israel
Rambam Health Care Campus Recruiting
Haifa, Israel
Principal Investigator: Tsila Zuckerman, MD         
Sponsors and Collaborators
Cellect Biotechnology
Investigators
Principal Investigator: Tsila Zuckerman, MD Rambam Hospital, Haifa, Israel
  More Information

Responsible Party: Cellect Biotechnology
ClinicalTrials.gov Identifier: NCT02828878     History of Changes
Other Study ID Numbers: ApoGraft 01
Study First Received: July 4, 2016
Last Updated: August 8, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Cellect Biotechnology:
Apoptosis
FAS Ligand
Bone marrow transplantation
GvHD
Stem cells

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases

ClinicalTrials.gov processed this record on September 19, 2017